Medivir AB – Product Pipeline Review – 2012

Date: May 28, 2012
Pages: 130
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M0CD4C95A4CEN
Leaflet:

Download PDF Leaflet

Medivir AB – Product Pipeline Review – 2012
Medivir AB – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Medivir AB - Product Pipeline Review - 2012” provides data on the Medivir AB’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Medivir AB’s corporate website, SEC filings, investor presentations and featured press releases, both from Medivir AB and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Medivir AB - Brief Medivir AB overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Medivir AB human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Medivir AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Medivir AB’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Medivir AB’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Medivir AB in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Medivir AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Medivir AB.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Medivir AB and identify potential opportunities in those areas.
Keywords

Current R&D Portfolio of Medivir AB; Medivir AB - Key Therapeutics; Medivir AB - Pipeline Overview and Promising Molecules; Medivir AB - News; Medivir AB - Latest Updates; Medivir AB - Pipeline; Medivir AB - Discontinued/Dormant Projects
Medivir AB Snapshot
Medivir AB Overview
Key Information
Key Facts
Medivir AB – Research and Development Overview
Key Therapeutic Areas
Medivir AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Medivir AB – Pipeline Products Glance
Medivir AB – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Medivir AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Medivir AB – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Medivir AB – Drug Profiles
Cathepsin S Inhibitors
Product Description
Mechanism of Action
R&D Progress
Cathepsin S Program
Product Description
Mechanism of Action
R&D Progress
HCV Polymerase Inhibitors
Product Description
Mechanism of Action
R&D Progress
HIV-PI
Product Description
Mechanism of Action
R&D Progress
MIV-160
Product Description
Mechanism of Action
R&D Progress
MIV-210
Product Description
Mechanism of Action
R&D Progress
MIV-710
Product Description
Mechanism of Action
R&D Progress
MIV-711
Product Description
Mechanism of Action
R&D Progress
NS3 Protease Inhibitor
Product Description
Mechanism of Action
R&D Progress
NS5A-Inhibitor
Product Description
Mechanism of Action
R&D Progress
Nucleoside-Based Polymerase Inhibitor
Product Description
Mechanism of Action
R&D Progress
TMC-435 + PSI-7977
Product Description
Mechanism of Action
R&D Progress
TMC435
Product Description
Mechanism of Action
R&D Progress
TMC435 + Daclatasvir
Product Description
Mechanism of Action
R&D Progress
TMC435 + PEGIFNalpha-2A + Ribavirin
Product Description
Mechanism of Action
R&D Progress
Medivir AB – Pipeline Analysis
Medivir AB – Pipeline Products by Therapeutic Class
Medivir AB – Pipeline Products By Target
Medivir AB – Pipeline Products by Route of Administration
Medivir AB – Pipeline Products By Mechanism of Action
Medivir AB – Recent Pipeline Updates
Medivir AB - Dormant Projects
Medivir AB - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BACE inhibitors
MIV-701
TMC649128
Medivir AB – Company Statement
Medivir AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Medivir AB, Recent Developments
Medivir AB- Press Release
Apr 19, 2012: Janssen Creates New Division To Launch TMC435 In EMEA
Apr 18, 2012: Medivir Announces Expanded Clinical Study Program Evaluating Combination Of TMC435 And Daclatasvir
Apr 18, 2012: Medivir Announces TMC435 In Expanded Clinical Collaboration With Bristol-Myers Squibb
Apr 04, 2012: Medivir Announces Acceptance Of Four TMC435 Abstracts For Presentation At EASL Meeting
Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711
Mar 13, 2012: Medivir Announces New Studies In Phase III Program For TMC435
Dec 21, 2009: Medivir Receives Approval Of Xerclear For The Treatment Of Herpes Cold Sores In Sweden
Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA
Sep 16, 2009: Medivir Presents Its Cathepsin K Program At The Ongoing 31st ASBMR Meeting In Denver
Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711
Apr 24, 2009: Tibotec Forms Alliance With Medivir To Develop TMC435 To Treat HCV
Apr 24, 2009: Tibotec To Present New Data On TMC435 At EASL
Feb 04, 2009: Medivir Designates MIV-710 A Candidate Drug (CD) For Osteoporosis And Osteoarthritis
Financial Deals Landscape
Medivir AB, Deals Summary
Medivir AB, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
BioPhausia Acquires Pharma Products Portfolio From AstraZeneca
BioPhausia Acquires Pharma Products Portfolio From AstraZeneca
Medivir Acquires Cathepsin S Project From Peptimmune
Partnerships
Medivir Enters Into Distribution Agreement With Daewoong Pharma For Xerclear
Medivir Enters Into Collaboration With Janssen Pharmaceutica
Medivir Enters Into Distribution Agreement With Daewoong Pharma
Medivir Enters Into Co-Marketing Agreement With GlaxoSmithKline
Medivir Extends Co-Development Agreement With Tibotec Pharma
Medivir Amends Its Agreement With Jiangsu Hengrui
Biovitrum Enters Into Research Collaboration With Medivir
Licensing Agreements
Medivir Enters Into Licensing Agreement With Daewoong Pharma
Medivir Extends Licensing Agreement With Tibotec Pharma
Meda Amends Licensing Agreement With Medivir For Xerese
GlaxoSmithKline Enters Into Licensing Agreement With Medivir
Meda Enters Into Licensing Agreement With Medivir
Medivir Enters Into Licensing Agreement With Tibotec
Medivir Enters Into Licensing Agreement With Hainan Noken For MIV-210
Medivir Enters Into Licensing Agreement With Beijing Mefuvir Medicinal Technology
Medivir Enters Into Licensing Agreement With Guangdong Lantai Viewland Pharma
Medivir Enters Into Licensing Agreement With Presidio
Bristol-Myers Squibb Enters Into Licensing Agreement With Medivir
Medivir Enters Into Licensing Agreement With Epiphany Biosciences For MIV-606
Medivir Enters Into Licensing Agreement With Epiphany Biosciences
Medivir Enters Into Licensing Agreement With Tibotec Pharma For HIV Project
Medivir Enters Into Licensing Agreement With Tibotec Pharma For MIV-210
Medivir Enters Into Licensing Agreement With Tibotec Pharma
Equity Offering
Medivir Prices Secondary Offering For $31 Million
Medivir Completes Private Placement Of $40 Million
Medivir Completes Rights Offering Of $45 Million
BioPhausia Completes Rights Issue Of $51 Million
Medivir Completes Rights Issue For $33 Million
BioPhausia Completes Private Placement Of $7 Million
Medivir Completes Rights Offering Of $43 Million
Asset Transactions
Meda Acquires OTC Products From BioPhausia
Acquisition
Bluefish Pharma Acquires BMM Pharma From BioPhausia
Medivir To Acquire BioPhausia
BioPhausia Acquires All gene Pharma For $0.9 Million
BioPhausia Acquires Cross Pharma From Meda
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Medivir AB, Key Information
Medivir AB, Key Facts
Medivir AB – Pipeline by Indication, 2012
Medivir AB – Pipeline by Stage of Development, 2012
Medivir AB – Monotherapy Products in Pipeline, 2012
Medivir AB – Combination Treatment Modalities in Pipeline, 2012
Medivir AB – Phase III, 2012
Medivir AB – Phase II, 2012
Medivir AB – Phase I, 2012
Medivir AB – Pre-Clinical, 2012
Medivir AB – Pipeline By Therapeutic Class, 2012
Medivir AB - Pipeline By Target, 2012
Medivir AB – Pipeline By Route of Administration, 2012
Medivir AB – Pipeline Products By Mechanism of Action, 2012
Medivir AB – Recent Pipeline Updates, 2012
Medivir AB - Dormant Developmental Projects,2012
Medivir AB - Discontinued Pipeline Products, 2012
Medivir AB, Other Locations
Medivir AB, Subsidiaries
Medivir AB, Deals Summary
BioPhausia Acquires Pharma Products Portfolio From AstraZeneca
BioPhausia Acquires Pharma Products Portfolio From AstraZeneca
Medivir Acquires Cathepsin S Project From Peptimmune
Medivir Enters Into Distribution Agreement With Daewoong Pharma For Xerclear
Medivir Enters Into Collaboration With Janssen Pharmaceutica
Medivir Enters Into Distribution Agreement With Daewoong Pharma
Medivir Enters Into Co-Marketing Agreement With GlaxoSmithKline
Medivir Extends Co-Development Agreement With Tibotec Pharma
Medivir Amends Its Agreement With Jiangsu Hengrui
Biovitrum Enters Into Research Collaboration With Medivir
Medivir Enters Into Licensing Agreement With Daewoong Pharma
Medivir Extends Licensing Agreement With Tibotec Pharma
Meda Amends Licensing Agreement With Medivir For Xerese
GlaxoSmithKline Enters Into Licensing Agreement With Medivir
Meda Enters Into Licensing Agreement With Medivir
Medivir Enters Into Licensing Agreement With Tibotec
Medivir Enters Into Licensing Agreement With Hainan Noken For MIV-210
Medivir Enters Into Licensing Agreement With Beijing Mefuvir Medicinal Technology
Medivir Enters Into Licensing Agreement With Guangdong Lantai Viewland Pharma
Medivir Enters Into Licensing Agreement With Presidio
Bristol-Myers Squibb Enters Into Licensing Agreement With Medivir
Medivir Enters Into Licensing Agreement With Epiphany Biosciences For MIV-606
Medivir Enters Into Licensing Agreement With Epiphany Biosciences
Medivir Enters Into Licensing Agreement With Tibotec Pharma For HIV Project
Medivir Enters Into Licensing Agreement With Tibotec Pharma For MIV-210
Medivir Enters Into Licensing Agreement With Tibotec Pharma
Medivir Prices Secondary Offering For $31 Million
Medivir Completes Private Placement Of $40 Million
Medivir Completes Rights Offering Of $45 Million
BioPhausia Completes Rights Issue Of $51 Million
Medivir Completes Rights Issue For $33 Million
BioPhausia Completes Private Placement Of $7 Million
Medivir Completes Rights Offering Of $43 Million
Meda Acquires OTC Products From BioPhausia
Bluefish Pharma Acquires BMM Pharma From BioPhausia
Medivir To Acquire BioPhausia
BioPhausia Acquires All gene Pharma For $0.9 Million
BioPhausia Acquires Cross Pharma From Meda

LIST OF FIGURES

Medivir AB – Pipeline by Indication, 2012
Medivir AB – Pipeline by Stage of Development, 2012
Medivir AB – Monotherapy Products in Pipeline, 2012
Medivir AB – Combination Treatment Modalities in Pipeline, 2012
Medivir AB – Pipeline By Therapeutic Class, 2012
Medivir AB - Pipeline By Target, 2012
Medivir AB – Pipeline By Route of Administration, 2012
Medivir AB - Pipeline Products By Mechanism of Action, 2012

Ask Your Question

Medivir AB – Product Pipeline Review – 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: